EBV BNRF1 (1238-1252)

Ref. 3D-CRB1001669

Informations sur le produit

• Nom: EBV BNRF1 (1238-1252)
• Synonymes: H-TDAWRFAMNYPRNPT-OH

Description

Cellular immunotherapy is an effective treatment option against Epstein-Barr virus (EBV)-driven lymphoproliferation in recipients of hematopoietic stem cells. However, increasing the number of identified epitope targets will help improve the response rate and success. Viral tegument protein BNRF1 is a critical target in EBV inducing specific CD4+ T-cell responses. 18 epitopes within BNRF1 are known, including (1238-1252). BNRF1-specific CD4+ T cells are cytotoxic and limit EBV-driven B cell transformation. Work with EBV BNRF1 (1238-1252) epitope and others will help improve T cell immunotherapy and our understanding of host-virus interaction.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1,838.9 g/mol